Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors.
OBJECTIVE
To evaluate the effect of tumour necrosis factor alpha (TNFalpha), interleukin (IL) 1beta, and their respective inhibitors the p75 TNFalpha soluble receptor (sTNFR) and the type II sIL1betaR (sIL1RII) on whole muscle and isolated myoblast activation.


METHODS
Normal muscle samples were stimulated for 7 days with TNFalpha alone or in combination with IL1beta, and myoblasts from these samples for 48 hours. IL6 production was measured by ELISA. Nuclear translocation of NF-kappaB was analysed by immunofluorescent staining and class I MHC expression by FACS.


RESULTS
TNFalpha and IL1beta induced IL6 production by normal muscle samples and myoblasts, the action of TNFalpha being more potent on muscle samples. Their soluble receptors (1 microg/ml) decreased this production. Suboptimal concentrations of TNFalpha and IL1beta induced NF-kappaB translocation. sTNFR markedly down regulated TNFalpha-induced translocation while sIL1RII was less potent on IL1beta-induced activation. NF-kappaB translocation induced by the combination of optimal concentrations of TNFalpha and IL1beta was completely inhibited by their soluble receptors. TNFalpha and to a lesser extent IL1beta induced class I MHC expression by myoblasts and this effect was completely inhibited by their respective soluble receptors.


CONCLUSIONS
These results suggest that TNFalpha and IL1beta should be targeted for myositis treatment.
Chevrel
G
G
Departments of Immunology and Rheumatology and INSERM Unit 403, Hôpital E, Herriot, Lyon, France.
Granet
C
C
Miossec
P
P
D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects; D004347:Drug Interactions; D000068800:Etanercept; D015395:Histocompatibility Antigens Class I / Q000378:metabolism; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D015850:Interleukin-6 / Q000096:biosynthesis*; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000378:metabolism; D032448:Myoblasts, Skeletal / Q000187:drug effects / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism*; D017472:Receptors, Interleukin-1; D053574:Receptors, Interleukin-1 Type II; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins / Q000494:pharmacology; D046509:Tissue Culture Techniques; D014178:Translocation, Genetic; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000494:pharmacology*
D015395:Histocompatibility Antigens Class I; D007074:Immunoglobulin G; D007375:Interleukin-1; D015850:Interleukin-6; D016328:NF-kappa B; D017472:Receptors, Interleukin-1; D053574:Receptors, Interleukin-1 Type II; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept
FASEB J. 2001 May;15(7):1169-80
11344085
J Immunol. 1998 Jul 1;161(1):409-14
9647250
J Immunol. 2001 Nov 15;167(10):6015-20
11698482
Cardiovasc Res. 2002 Apr;54(1):95-104
12062366
J Rheumatol Suppl. 2002 Sep;65:16-21
12236617
J Neuroimmunol. 2003 Apr;137(1-2):125-33
12667656
Rheumatology (Oxford). 2004 Apr;43(4):524-6
15024139
Arthritis Res Ther. 2004;6(3):R190-8
15142264
Eur Neurol. 2004;52(1):61-3
15240986
N Engl J Med. 1991 Nov 21;325(21):1487-98
1658649
Immunol Today. 1994 Jun;15(6):269-74
8068173
J Neuroimmunol. 1995 Dec;63(1):9-16
8557829
Arthritis Rheum. 1997 May;40(5):865-74
9153548
Int Immunol. 1998 Mar;10(3):267-73
9576614
Acta Neuropathol. 2000 May;99(5):585-8
10805105
Arthritis Rheum. 2001 Jun;44(6):1293-303
11407688